Lundbeck and Myriad to further investigate Flurizan trials

Lundbeck and Myriad have announced they are to explore further the results from the phase III trial of Flurizan (tarenflurbil).

The phase III trial of the drug – which is targeted at patients suffering from mild Alzheimer’s disease – did not correspond with the phase II trial.

Executive vice-president Anders Gersel Pedersen, head of drug development at Lundbeck, said Alzheimer’s disease is an area where medical advances are perhaps the most needed.

“Lundbeck is a leading player in brain disorders and despite the inherent risk we will continue to develop new pharmaceuticals for the treatment of the disease either in-house or through in-licensing,” he added.

The trial found symptoms were “well balanced” between the placebo and Flurizan.

Alzheimer’s disease affects between five and six million people in Europe – 30 per cent are aged over 85 years old.

As well as Alzheimer’s disease, Lundbeck also researches Parkinson’s disease, schizophrenia and depression.